| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2014 | US20140113875 Novel self-assembling drug amphiphiles and methods for synthesis and use |
| 04/24/2014 | US20140113012 Compounds and methods for inducing chondrogenesis |
| 04/24/2014 | US20140113009 Controlled application of cross-linking agent |
| 04/24/2014 | US20140113005 Compounds useful as inhibitors of atr kinase |
| 04/24/2014 | US20140113004 Compositions and Methods for the Prevention of Esophageal Cancer |
| 04/24/2014 | US20140113000 Compositions Comprising Peroxyacid and Methods for Producing and Using the Same |
| 04/24/2014 | US20140112996 Dosage forms for oral administration and methods of treatment using the same |
| 04/24/2014 | US20140112995 Multi-layered, multiple unit pharmaceutical compositions |
| 04/24/2014 | US20140112994 Method for Making Medical Devices Having Antimicrobial Coatings Thereon |
| 04/24/2014 | US20140112993 Freeze-dried aripiprazole formulation |
| 04/24/2014 | US20140112992 Process for febuxostat |
| 04/24/2014 | US20140112989 Abuse-proofed oral dosage form |
| 04/24/2014 | US20140112988 Pharmaceutical Composition and Administrations Thereof |
| 04/24/2014 | US20140112987 Gastroresistant pharmaceutical formulations containing rifaximin |
| 04/24/2014 | US20140112986 Proliposomal testosterone formulations |
| 04/24/2014 | US20140112984 Crush resistant delayed-release dosage forms |
| 04/24/2014 | US20140112983 Nitrite compositions and uses thereof |
| 04/24/2014 | US20140112981 Controlled release hydrocodone formulations |
| 04/24/2014 | US20140112980 Abuse-resistant pharmaceutical compositions |
| 04/24/2014 | US20140112976 Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity |
| 04/24/2014 | US20140112974 Ropinirole-containing patch and package thereof |
| 04/24/2014 | US20140112970 Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| 04/24/2014 | US20140112968 Adhesive composition for carrying therapeutic agents as delivery vehicle on coating applied to vascular grafts |
| 04/24/2014 | US20140112962 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
| 04/24/2014 | US20140112957 Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form |
| 04/24/2014 | US20140112945 Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives |
| 04/24/2014 | US20140112941 Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
| 04/24/2014 | US20140112939 Methods for Inhibiting Osteolysis |
| 04/24/2014 | US20140112935 Antibodies to interleukin-6 and use thereof |
| 04/24/2014 | US20140112932 Methods for Treating GI Syndrome and Graft versus Host Disease |
| 04/24/2014 | US20140112920 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 04/24/2014 | US20140112918 Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck |
| 04/24/2014 | US20140112907 Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 04/24/2014 | US20140112904 Method for enhancing the cleavage activity of i-crei derived meganucleases |
| 04/24/2014 | US20140112900 Solubilized CoQ-10 |
| 04/24/2014 | US20140112888 Viral Hepatitis Treatment |
| 04/24/2014 | US20140112887 2',4'-bridged nucleosides for hcv infection |
| 04/24/2014 | US20140112886 Dinucleotide compounds for hcv infection |
| 04/24/2014 | US20140112885 Antiviral compounds |
| 04/24/2014 | US20140112882 Methods to treat pancreatic inflammation and associated lung injury through regulation of pancreatic interleukin-22 expression |
| 04/24/2014 | US20140112878 Tyrosinase Inhibitor |
| 04/24/2014 | US20140109916 Transdermal Delivery of Hormones without the Need of Penetration Enhancers |
| 04/24/2014 | DE202005022112U1 Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester Pharmaceutical controlled release compositions comprising a fumaric ester |
| 04/24/2014 | DE102012110009A1 Mittel zur Linderung oder gegen Migräneschmerzen Means for alleviating or migraine pain |
| 04/24/2014 | DE102012105512A1 Arzneiform zur verlängerten Freisetzung von Wirkstoffen Dosage form for the prolonged release of active ingredients |
| 04/24/2014 | DE102012020542A1 Use of an active ingredient consisting of e.g. tocotrienols in the substantial absence of tocopherols, for the prevention or treatment of e.g. normal or pathological inflammatory diseases, pain, diseases of nervous system, and cancer |
| 04/23/2014 | EP2722334A1 Benzodiazepine bromodomain inhibitor |
| 04/23/2014 | EP2722333A1 Spiro-indole derivatives for the treatment of parasitic diseases. |
| 04/23/2014 | EP2722332A1 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
| 04/23/2014 | EP2722331A1 Crystal of pyrroloquinolinequinone disodium salt, and method for producing same |
| 04/23/2014 | EP2722329A1 Indol-amide compounds as beta-amyloid inhbitors |
| 04/23/2014 | EP2722328A1 Novel compounds with protective activity against toxins with intracellular action mode |
| 04/23/2014 | EP2722327A1 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine |
| 04/23/2014 | EP2722326A1 Quinone based nitric oxide donating compounds |
| 04/23/2014 | EP2722322A2 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient |
| 04/23/2014 | EP2722054A1 Methods and compositions for oral administration of proteins |
| 04/23/2014 | EP2722049A1 A pharmaceutical composition for inhibiting recurrence, aggravation and metastasis of hepatocarcinoma |
| 04/23/2014 | EP2722048A1 Iron bisglycinate chelate for use in treating anaemia |
| 04/23/2014 | EP2722047A1 2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections |
| 04/23/2014 | EP2722046A1 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 1 |
| 04/23/2014 | EP2722045A2 Compositions for treating centrally mediated nausea and vomiting |
| 04/23/2014 | EP2722044A1 Compositions for treating centrally mediated nausea and vomiting |
| 04/23/2014 | EP2722043A1 Process for Stimulating Hyaluronic Acid Production with Ascorbic Acid Derivatives and the Composition Thereof |
| 04/23/2014 | EP2722042A2 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases |
| 04/23/2014 | EP2722041A1 Therapeutic agent for allergic rhinitis |
| 04/23/2014 | EP2722040A1 Lidocaine-containing cataplasm |
| 04/23/2014 | EP2722038A2 Lipid Composition |
| 04/23/2014 | EP2722037A1 Prasugrel formulations |
| 04/23/2014 | EP2722036A1 Solid oral formulations of prasugrel |
| 04/23/2014 | EP2722035A1 Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 04/23/2014 | EP2722034A1 Oral Pharmaceutical Formulations Comprising Dabigatran |
| 04/23/2014 | EP2722033A1 Pharmaceutical Compositions of Dabigatran Free Base |
| 04/23/2014 | EP2721157A1 New treatment for muscular dystrophies |
| 04/23/2014 | EP2721063A1 Pcsk9-binding polypeptides and methods of use |
| 04/23/2014 | EP2721047A2 Methods for the synthesis and purification of deoxycholic acid |
| 04/23/2014 | EP2721040A1 Bifunctional phosphonate chelating agents |
| 04/23/2014 | EP2721036A1 Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
| 04/23/2014 | EP2721035A1 Glioblastoma inhibiting compounds and their use |
| 04/23/2014 | EP2721033A1 Compounds, their pharmaceutical compositions and their uses as idh1 mutants inhibitors for treating cancers |
| 04/23/2014 | EP2721032A2 Polyhedral cage-containing metalloporphyrin frameworks, methods of making, and methods of using |
| 04/23/2014 | EP2721031A2 Bromodomain inhibitors and uses thereof |
| 04/23/2014 | EP2721030A1 Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives |
| 04/23/2014 | EP2721028A1 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| 04/23/2014 | EP2721026A1 Phosphate esters of gyrase and topoisomerase inhibitors |
| 04/23/2014 | EP2721025A1 New selective ccr2 antagonists |
| 04/23/2014 | EP2721024A1 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids |
| 04/23/2014 | EP2721023A1 Metalloenzyme inhibitor compounds |
| 04/23/2014 | EP2721020A2 Metalloenzyme inhibitor compounds |
| 04/23/2014 | EP2721019A1 Therapeutically active compositions and their methods of use |
| 04/23/2014 | EP2721014A2 Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation |
| 04/23/2014 | EP2721013A1 Process for the preparation of a chiral compound |
| 04/23/2014 | EP2721012A1 Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mglu2 receptor agonist |
| 04/23/2014 | EP2721011A1 Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| 04/23/2014 | EP2721009A1 Pyrazole derivatives useful as aldosterone synthase inhibitors |
| 04/23/2014 | EP2721008A1 Hydroxy substituted isoquinolinone derivatives |
| 04/23/2014 | EP2721007A1 Cyclohexyl isoquinolinone compounds |
| 04/23/2014 | EP2721004A1 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| 04/23/2014 | EP2721003A1 Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| 04/23/2014 | EP2720989A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
| 04/23/2014 | EP2720720A1 Combination therapy to prevent dcis formation and progression to breast cancer |